Feedback

Effect of tanshinone IIA for myocardial ischemia/reperfusion injury in animal model: preclinical evidence and possible mechanisms

Affiliation
Department of Cardiology ,Lishui Hospital of Zhejiang University ,The Fifth Affiliated Hospital of Wenzhou Medical University ,Lishui Municipal Central Hospital ,Lishui ,China
Zhu, Peng-Chong;
Affiliation
Department of Cardiology ,Lishui Hospital of Zhejiang University ,The Fifth Affiliated Hospital of Wenzhou Medical University ,Lishui Municipal Central Hospital ,Lishui ,China
Shen, Jiayi;
Affiliation
Department of Cardiology ,Lishui Hospital of Zhejiang University ,The Fifth Affiliated Hospital of Wenzhou Medical University ,Lishui Municipal Central Hospital ,Lishui ,China
Qian, Ren-Yi;
Affiliation
Department of Cardiology ,Lishui Hospital of Zhejiang University ,The Fifth Affiliated Hospital of Wenzhou Medical University ,Lishui Municipal Central Hospital ,Lishui ,China
Xu, Jian;
Affiliation
Department of Cardiology ,Lishui Hospital of Zhejiang University ,The Fifth Affiliated Hospital of Wenzhou Medical University ,Lishui Municipal Central Hospital ,Lishui ,China
Liu, Chong;
Affiliation
Department of Cardiology ,Lishui Hospital of Zhejiang University ,The Fifth Affiliated Hospital of Wenzhou Medical University ,Lishui Municipal Central Hospital ,Lishui ,China
Hu, Wu-Ming;
Affiliation
Department of Gynaecology and Obstetrics ,The First Affiliated Hospital of Jiamusi University ,Jiamusi ,China
Zhang, Ying;
Affiliation
Department of Cardiology ,Lishui Hospital of Zhejiang University ,The Fifth Affiliated Hospital of Wenzhou Medical University ,Lishui Municipal Central Hospital ,Lishui ,China
Lv, Ling-Chun

Introduction: Tanshinone IIA (Tan IIA), the major active lipophilic ingredient of Radix Salviae Miltiorrhizae , exerts various therapeutic effects on the cardiovascular system. We aimed to identify the preclinical evidence and possible mechanisms of Tan IIA as a cardioprotective agent in the treatment of myocardial ischemia/reperfusion injury. Methods: The study quality scores of twenty-eight eligible studies and data analyses were separately assessed using the CAMARADES 10-item checklist and Rev-Man 5.3 software. Results: The study quality score ranged from 3/10 to 7/10 points. The present study provided preliminary preclinical evidence that Tan IIA could significantly decrease the myocardial infarct size, cardiac enzyme activity and troponin levels compared with those in the control group ( p < 0.05 ). Discussion: Tan IIA alleviated myocardial I/R injury via antioxidant, anti-inflammatory, anti-apoptosis mechanisms and improved circulation and energy metabolism. Thus, Tan IIA is a promising cardioprotective agent for the treatment of myocardial ischemia/reperfusion injury and should be further investigated in clinical trials.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2023 Zhu, Shen, Qian, Xu, Liu, Hu, Zhang and Lv.

Use and reproduction: